绝经后转移性乳腺癌患者在使用非甾体类芳香化酶抑制剂后，依西美坦作为进一步激素治疗的临床评估。

Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.

作者信息

Carlini Paolo, Michelotti Andrea, Ferretti Gianluigi, Ricci Sergio, Giannarelli Diana, Pellegrini Manuela, Cresti Nicola, Di Cosimo Serena, Bria Emilio, Papaldo Paola, Fabi Alessandra, Ruggeri Enzo Maria, Milella Michele, Alimonti Andrea, Salesi Nello, Cognetti Francesco

机构信息

Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy.

出版信息

Cancer Invest. 2007 Mar;25(2):102-5. doi: 10.1080/07357900701224789.

DOI:10.1080/07357900701224789

PMID:17453821

Abstract

OBJECTIVES

The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic breast cancer women. Few clinical data are published on the sequential use of different classes of aromatase inhibitors.

METHODS

We report an analysis on 30 postmenopausal metastatic breast cancer women treated between January 2000 and May 2002 in 2 Italian Oncology Institutions with the hormonal sequence n-SAI (Anastrozole, Letrozole) --> Exemestane.

RESULTS

When receiving n-SAI (Anastrozole 8 patients and Letrozole 22 patients), 1 out of 30 women achieved a partial response, 20 of 30 patients no change (NC) > or =6 months. The analysis of the entire population treated with Exemestane showed an overall clinical benefit (CB) of 46.6 percent (14/30) with a median duration of 12 months (95%CI 6-25) and a median time to progression (TTP) of 4 months (95%CI 1-25).

CONCLUSIONS

These data confirm a partial lack of cross-resistance between n-SAI --> Exemestane given in sequence.

摘要

目的

芳香化酶抑制剂阿那曲唑、来曲唑（2型非甾体芳香化酶抑制剂：n - SAI）和依西美坦（1型甾体芳香化酶灭活剂）分别用于绝经后转移性乳腺癌女性的一线和二线激素治疗。关于不同类别芳香化酶抑制剂序贯使用的临床数据鲜有发表。

方法

我们报告了对2000年1月至2002年5月期间在2家意大利肿瘤机构接受激素序贯治疗n - SAI（阿那曲唑、来曲唑）→依西美坦的30例绝经后转移性乳腺癌女性的分析。

结果

接受n - SAI治疗时（阿那曲唑8例患者，来曲唑22例患者），30例女性中有1例获得部分缓解，30例患者中有20例无变化（NC）≥6个月。对接受依西美坦治疗的全部人群的分析显示，总体临床获益（CB）为46.6%（14/30），中位持续时间为12个月（95%CI 6 - 25），中位疾病进展时间（TTP）为4个月（95%CI 1 - 25）。